PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients
Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Renrong Wu(Central South University), Zhuang Peng(Hunan University), Mengxi Sun(Huazhong Agricultural University), Manjun Shen(Central South University), Xingjie Peng(Central South University), Jingping Zhao(Central South University), Tiannan Shao(Second Affiliated Hospital of Zhejiang University), Ye Yang(Seoul National University), Yujun Long(Second Xiangya Hospital of Central South University), Xiaoyi Wang(Hubei University of Medicine), Peng Xie(Central South University), Jingmei Xiao(Central South University), Weiyan Wang(Central South University), Ping Shao(Tianjin Children's Hospital), Dongyu Kang(Central South University)
Cited by 16
Related Papers
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
|British Journal of Cancer|2018|156
Stress Impairs Reconsolidation of Drug Memory via Glucocorticoid Receptors in the Basolateral Amygdala
|Journal of Neuroscience|2008|142